The World Dermatological Market Outlook, 2009-2023

1 Executive Summary
1.1 Dermatological Market Review
1.2 Aims, Scope and Format of the Report

2 Introduction to Skin Diseases and Treatments
2.1 The Structure of the Skin
2.1.1 Hair
2.1.2 Sweat and Sebaceous Glands
2.1.3 Nails
2.2 The Physiological Role of the Skin
2.2.1 Protection
2.2.2 Sensory Perception
2.2.3 Storage
2.2.4 Absorption/Vitamin D Formulation
2.2.5 Temperature Regulation
2.3 Differences in Skin Due to Gender
2.4 The Effects of Age on Skin Structure
2.5 Inflammation and Histamine Release
2.6 Introduction to Dermatitis
2.6.1 Atopic Dermatitis
2.6.2 Contact Dermatitis
2.6.3 Seborrheic Dermatitis
2.7 Introduction to Rosacea
2.7.1 Symptoms
2.7.2 Types and Causation
2.8 Introduction to Urticaria
2.8.1 Acute Urticaria
2.8.2 Chronic Urticaria
2.8.3 Physical Urticaria
2.8.4 Dermatographic Urticaria
2.9 Introduction to Alopecia
2.9.1 Alopecia Areata
2.9.2 Androgenic Alopecia
2.9.3 Telogen Effluvium
2.9.4 Trichotillomania and Traction Alopecia
2.10 Introduction to Skin Infection
2.10.1 Bacterial Skin Infections
2.10.2 Fungal Skin Infections
2.10.2.1 Dermatophyte Infections
2.10.3 Viral Infections
2.10.3.1 Herpes Simplex
2.10.3.2 Chicken Pox
2.10.3.3 Herpes Zpster
2.10.3.4 Warts
2.11 Introduction to Acne
2.11.1 Pathogenesis
2.11.2 Causation
2.11.3 The Diagnosis of Acne
2.12 Introduction to Psoriasis
2.12.1 Causation
2.12.2 Symptoms
2.12.3 Type
2.12.4 Complications
2.13 Common Skin Treatments
2.13.1 Creams and Semisolid Emulsions
2.13.2 Ointments
2.13.3 Lotions
2.13.4 Solutions
2.13.5 Occlusive Therapy
2.13.6 Cleansing Agents
2.13.7 Protectant Powders and Hydrophilic Polymers
2.13.8 Anti-Infective Agents
2.13.9 Anti-Inflammatory Agents

3 An Overview of the World Dermatological Market 2008-2023 (Including Forecasts in the Seven Major Markets)
3.1 The World Dermatological Market Analysis
3.1.1 Strategic Analysis
3.2 The Leading Dermatological Markets: a Comparison
3.3 Medrol Currently Leads the World Dermatological Market – But Will it Last?
3.4 The Dermatitis Market Dominates the Dermatological Industry
3.5 Pharmaceutical Companies Accept that Dermatological Blockbuster Sales Will Be Difficult to Achieve
3.6 While the Past Has Been Difficult for Dermatological Treatments, There is Optimism for the Future
3.7 The Top 10 Companies in the Dermatological Market
3.8 The Dermatological Market, Regional Breakdown
3.9 Dermatological Sales in the Seven Major Markets
3.9.1 Dermatological Market in the US
3.9.2 Dermatological Market in Japan
3.9.3 Dermatological Market in France
3.9.4 Dermatological Market in Germany
3.9.5 Dermatological Market in the UK
3.9.6 Dermatological Market in Italy
3.9.7 Dermatological Market in Spain

4 The World Dermatitis Market Analysis 2008-2023
4.1 Dermatitis Market Analysis - Overview
4.2 Medrol Currently Leads the Dermatitis and Dermatological Market
4.2.1 Development of Medrol (methylprednisolone acetate)
4.3 Celestone Analysis
4.3.1 Development of Celestone (betamethasone)
4.4 Elocon Suffers From Generic Competition
4.4.1 Development of Elocon (mometasone fuorate)
4.5 Dermovate Will Increase in Revenues During 2008-2013 – But Will Growth Last Beyond that Period
4.5.1 Development of Dermovate/Olux/Clob X (Clobetasol)
4.6 Kenacort A to Show an Early Increase in Revenues
4.6.1 Kenacort A
4.7 The Dermatitis Market – Summary

5 The World Skin Infection Market Analysis 2008-2023
5.1 Skin Infection Market Analysis – Overview
5.2 Aldara Currently Leads the Skin Infection Market – But Will it Hold During the Forecast Period
5.2.1 Development of Aldara (imiquimod)
5.3 Zovirax Will Show an Early Increase in Revenues
5.3.1 Development of Zovirax (acyclovir)
5.4 Bactroban Will Decline in Revenues During the Forecast Period
5.4.1 Development of Bactroban (mupirocin)
5.5 Lamisil Will be Affected by Patent Expiration
5.5.1 Development of Lamisil (terbinafine)
5.6 Nizoral Will Suffer from Generic Competition
5.6.1 Development of Nizoral (ketoconazole)
5.7 The Skin Infection Market – Summary

6 The World Acne Market Analysis 2008-2023
6.1 Acne Market Analysis – Overview
6.2 Differin Currently Leads the Acne Market
6.2.1 Development of Differin (Adapalene)
6.3 Diane Open to Generic Competition
6.3.1 Development of Diane (cyproterone/ethinylestradiol)
6.4 Benzaclin Will Exhibit Positive Growth – However Can it Withstand Pressure From its Main Rival?
6.4.1 Benzoyl Peroxide and Clindamycin (Benzaclin and Duac)
6.5 Roaccutane Associated With Side Effects
6.5.1 Development of Roaccutane (isotretinoin)
6.6 Duac Revenues During the Forecast Period
6.7 The Acne Market – Summary

7 The World Psoriasis Market Analysis 2008-2023
7.1 Psoriasis Market Analysis – Overview
7.2 Raptiva Currently Leads the Psoriasis Market
7.2.1 Development of Raptiva (efalizumab)
7.3 Daivobet Growth During the Forecast Period
7.4 Dovonex Will Suffer From Strong Competition
7.5 Taclonex Sales Trends
7.5.1 Dovonex/Daivobet/Taclonex (calciportiene/betamethasone)
7.6 Soriatane Sales Will Be Boosted by its Strong Efficacy in Psoriasis Treatment
7.6.1 Soriatane (acitretin)
7.7 The Psoriasis Market – Summary

8 The World Market for Miscellaneous Dermatologicals 2008-2023
8.1 Miscellaneous Market Analysis
8.2 Proscar Sales Trends from 2008-2023
8.3 Will Surgicel Show Positive Sales Growth?
8.4 Betadine Shows Some Positive Growth - But Will it Continue?
8.5 The Miscellaneous Market – Summary

9 SWOT Analysis of the Dermatological Market
9.1 SWOT Analysis
9.2 Market Drivers
9.3 Market Restraints
9.4 There is Scope for Expansion into Related Markets
9.5 Advances in Technology Likely to Bring Benefits to the Market
9.6 Consumer Bargaining Power
9.7 Comparative Studies - a Two Edged Sword
9.8 Competition in the Dermatological Market to Become Increasingly Marked
9.9 Substitutes and Related Threats
9.10 A Discussion of Generic Drugs in This Market - How Great is Their Competitive Threat?

10 Pipeline Developments in the Dermatological Market
10.1 The Potential of the Dermatological Market Has Encouraged R&D
10.2 New Technology Leads to Interesting Pipeline Developments
10.3 Potential Entrants
10.4 Late-Stage Pipeline Products in the Dermatitis Sector
10.5 Late-Stage Pipeline Products in the Skin Infection Sector
10.6 Late-Stage Pipeline Products in the Acne Sector
10.7 Late-Stage Pipeline Products in the Psoriasis Sector
10.8 Late-Stage Pipeline Products in the Miscellaneous Sector
10.9 Innovation Rules for Early-Stage Pipeline Drugs

11 Conclusions
11.1 The Dermatological Market is Heading for Gradual Financial Growth
11.2 Market Drivers in the Dermatological Sector
11.3 Market Restraints in the Dermatological Sector
11.4 Medrol Currently Leads the World Dermatological Market
11.5 Will the Dermatitis Market Continue to Dominate?
11.6 The Skin Infection Market
11.7 The Acne Market
11.8 The Psoriasis Market
11.9 Why Growth in the Overall World Dermatological Market Will Continue

List of Tables
Table 3.1 The World Dermatological Market Forecast ($m), 2008-2023
Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Dermatological Markets, 2007 & 2013
Table 3.3 Top Ten Products in the Dermatological Market ($m), 2007
Table 3.4 Top 10 Companies Revenues ($m) in the Dermatological Market, 2007
Table 3.5 Dermatological Market Revenues ($m), Sales by Region 2007
Table 3.6 Dermatological Market Forecast ($m) in the Seven Major Markets, 2008-2023
Table 3.7 Dermatological Market Share (%) Comparison in the Seven Major Markets, 2007, 2010 & 2013
Table 4.1 The World Dermatitis Market ($m) Forecast 2008-2023
Table 4.2 Top 5 Products Rank Comparison, 2007 and 2023
Table 5.1 The World Skin Infection Market ($m) Forecast 2008-2023
Table 5.2 Top 5 Products Rank Comparison, 2007 and 2023
Table 6.1 The World Acne Market ($m) Forecast 2008-2023
Table 6.2 Top 5 Products Rank Comparison, 2007 and 2023
Table 7.1 The World Psoriasis Market ($m) Forecast 2008-2023
Table 7.2 Top 5 Leading Products Rank Comparison, 2007 and 2023
Table 8.1 The World Miscellaneous Treatments Market ($m) Forecast, 2008-2023
Table 9.1 SWOT Chart for the Dermatological Market, 2008-2023
Table 10.1 Late-Stage Pipeline Drugs for Skin Infection, 2008
Table 10.2 Late-Stage Pipeline Drugs for Acne, 2008
Table 10.3 Late-Stage Pipeline Drugs for Psoriasis, 2008
Table 10.4 Late-Stage Pipeline Drugs for Miscellaneous Disorders, 2008
Table 11.1 Leading Dermatological Markets Revenue Forecasts ($m), 2008-2023

List of Figures
Figure 3.1 The Leading Dermatological Markets Revenue ($m), 2008-2023
Figure 3.2 Leading Dermatological Markets Revenue ($m) Comparison, 2007 & 2013
Figure 3.3 Leading Dermatological Sectors Market Share (%), 2007
Figure 3.4 Leading Dermatological Sectors Market Share (%), 2013
Figure 3.5 Top Ten Products Revenue ($m) in the Dermatological Market, 2007*
Figure 3.6 Market Share (%) of Top Ten Dermatological Products, 2007
Figure 3.7 Market Share (%) of the Top 10 Companies, 2007
Figure 3.8 Market Share (%) of the Dermatological Market by Region, 2007
Figure 3.9 Dermatological Market Revenue ($m) in the Seven Major Markets, 2007*
Figure 3.10 Dermatological Market Share (%) in the Seven Major Markets, 2007
Figure 3.11 Dermatological Market Share (%) in the Seven Major Markets, 2010
Figure 3.12 Dermatological Market Share (%) in the Seven Major Markets, 2013
Figure 4.1 Market Share (%) of Leading Dermatitis Products, 2007
Figure 4.2 Market Share (%) of Leading Dermatitis Products, 2010
Figure 4.3 Market Share (%) of Leading Dermatitis Products, 2013
Figure 4.4 Dermatitis Market Revenue Forecast ($m), 2008-2023
Figure 4.5 Medrol Revenue Forecast ($m), 2008-2023
Figure 4.6 Celestone Revenue Forecast ($m), 2008-2023
Figure 4.7 Elocon Revenue Forecast ($m), 2008-2023
Figure 4.8 Dermovate Revenue Forecast ($m), 2008-2023
Figure 4.9 Kenacort A Revenue Forecast ($m), 2008-2023
Figure 5.1 Market Share (%) of the Leading Skin Infection Products, 2007
Figure 5.2 Market Share (%) of the Leading Skin Infection Products, 2010
Figure 5.3 Market Share (%) of the Leading Skin Infection Products, 2013
Figure 5.4 Skin Infection Market Revenue Forecast ($m), 2008-2023
Figure 5.5 Aldara Revenue Forecast ($m), 2008-2023
Figure 5.6 Zovirax Revenue Forecast ($m), 2008-2023
Figure 5.7 Bactroban Revenue Forecast ($m), 2008-2023
Figure 5.8 Lamisil Revenue Forecast ($m), 2008-2023
Figure 5.9 Nizoral Revenue Forecast ($m), 2008-2023
Figure 6.1 Market Share (%) of the Leading Acne Products, 2007
Figure 6.2 Market Share (%) of the Leading Acne Products, 2010
Figure 6.3 Market Share (%) of the Leading Acne Products, 2013
Figure 6.4 Acne Market Revenue Forecast ($m), 2008-2023
Figure 6.5 Differin Revenue Forecast ($m), 2008-2023
Figure 6.6 Diane Revenue Forecast ($m), 2008-2023
Figure 6.7 Benzaclin Revenue Forecast ($m), 2008-2023
Figure 6.8 Roaccutane Revenue Forecast ($m), 2008-2023
Figure 6.9 Duac Revenue Forecast ($m), 2008-2023
Figure 7.1 Market Share (%) of the Leading Psoriasis Products, 2007
Figure 7.2 Market Share (%) of the Leading Psoriasis Products, 2010
Figure 7.3 Market Share (%) of the Leading Psoriasis Products, 2013
Figure 7.4 Psoriasis Market Revenue Forecast ($m), 2008-2023
Figure 7.5 Raptiva Revenue Forecast ($m), 2008-2023
Figure 7.6 Daivobet Revenue Forecast ($m), 2008-2023
Figure 7.7 Dovonex Revenue Forecast ($m), 2008-2023
Figure 7.8 Taclonex Revenue Forecast ($m), 2008-2023
Figure 7.9 Soriatane Revenue Forecast ($m), 2008-2023
Figure 8.1 Market Share (%) of the Leading Miscellaneous Products, 2007
Figure 8.2 Market Share (%) of the Leading Miscellaneous Products, 2010
Figure 8.3 Market Share (%) of the Leading Miscellaneous Products, 2013
Figure 8.4 Miscellaneous Market Revenue Forecast ($m), 2008-2023
Figure 8.5 Proscar Revenue Forecast ($m), 2008-2023
Figure 8.6 Surgicel Revenue Forecast ($m), 2008-2023
Figure 8.7 Betadine Revenue Forecast ($m), 2008-2023